Thursday, September 15, 2011

Theravance superbug drug wins European OK

European regulators approved a drug developed by Theravance Inc. to treat the superbug MRSA in patients with hospital-acquired pneumonia.
The European Commission gave marketing approval Thursday to Astellas Pharma Europe Ltd., which signed a deal in 2005 with South San Francisco-based Theravance (NASDAQ: THRX). The drug, Vibativ, is a once-daily injectable to treat Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus, or MRSA.

No comments:

Post a Comment